Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
Sandrine Degryse(VIB-KU Leuven Center for Cancer Biology), Matthew D. Dun(Hunter Medical Research Institute)
Cited by 88
Related Papers
Proteomic Profiling of Mouse Epididymosomes Reveals their Contributions to Post-testicular Sperm Maturation
|Molecular & Cellular Proteomics|2018|225